// App-Quantinova.ai

1509 : In silico prediction of the clinical response to the mTOR inhibitor everolimus using a Boolean model: validation from a cohort of the SHIVA trial

Researchers

Presenter

  • Loic Verlingue

Principal Investigators

  • Laurence Calzone

  • Maud Kamal

  • Nicolas Servant

  • Lisa Belin

  • Emmanuel Barillot

  • Christophe Le Tourneau

Medical Centers

  • Institut Curie, Paris Cedex, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • Serine/threonine-protein kinase mTOR

  • PI3K/AKT

Drug/Treatment

  • Everolimus

Outcome

  • N/A

Study Design

  • Pharmacodynamics

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved